Associations Between Complementary Feeding Approach, Dietary Intake, and Growth: A Secondary Analysis of the Maternal and Infant Nutrition Trial.

J Acad Nutr DietMay 19, 2026 (epub)
Clinical ResearchPediatricsOpen access

Kinzie L Matzeller, Mikayla L Hernandez, Gabrielle N E Glime et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of a randomized controlled trial evaluated the growth and dietary intake of 144 infants aged 5 to 12 months following baby-led weaning (BLW) versus conventional weaning (CW). At 9 months, BLW infants had higher sodium intake (437 mg vs 294 mg; P < .001) and different macronutrient distributions, but no significant differences in growth outcomes were observed between the two groups.

Key findings

  • At 9 months, BLW infants had higher sodium intake (437 mg vs 294 mg; P < .001).
  • BLW infants had a higher percent energy from fat (47% vs 43%; P < .001) and lower from carbohydrates (43% vs 50%; P < .001) at 9 months.
  • No significant differences in rapid weight gain or growth z scores were observed between BLW and CW.

Why it matters

Understanding the impact of different complementary feeding approaches on nutrient intake and growth is crucial for pediatric care. This study suggests that both BLW and CW can support similar growth outcomes, which may influence feeding recommendations for infants.

Source

PubMed · PMID 42162611Free full text on PubMed Central

Published in J Acad Nutr Diet. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.